Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma
Chelsae R Watters(Mayo Clinic in Arizona), Mitesh J. Borad(Jacksonville College), Natalie Elliott(Mayo Clinic in Arizona), Mia Y. Masuda(Mayo Clinic in Arizona), Khandoker Usran Ferdous(Winthrop Rockefeller Foundation), Mulu Z. Tesfay(Winthrop Rockefeller Foundation), Omeed Moaven(Louisiana State University), Oumar Barro(Mayo Clinic in Arizona), Michael T. Barrett(Mayo Clinic in Arizona), Musa Gabere(Mayo Clinic in Arizona), Bolni Marius Nagalo(University of Arkansas for Medical Sciences), Elizabeth A. Raupach(Translational Genomics Research Institute), Yumei Zhou(Mayo Clinic in Arizona), Kenneth H. Buetow(Arizona State University)
Cited by 3
Related Papers
PID: the Pathway Interaction Database
|Nucleic Acids Research|2008|1.6k
A Comprehensive Human Linkage Map with Centimorgan Density
|Science|1994|537
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
|Nature Communications|2015|484
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423